The next stage: molecular epidemiology.

The traditional approach in epidemiology of relating exposure to an environmental agent such as a drug or infective agent has been to measure an overall risk (i.e., average and then "adjust risk for demographic variables and other confounders"). An attempt is sometimes made to define a "susceptible" subgroup. The analyses are usually based on good statistical methodology rather than an understanding of the interaction of body of host and agent. A twofold risk for 1000 exposed versus nonexposed people could be an average twofold risk for all 1000 exposed or a 20-fold risk for 100 exposed individuals (i.e., a drug-host interaction). Clearly, finding the 100 individuals with a 20-fold risk has much greater clinical importance than a twofold risk for 1000 people. The world of epidemiology may be changing-we may soon be able to define risk based on genetic susceptibility, at least sometimes.

[1]  M. Kocova,et al.  Autoimmunity and genetics contribute to the risk of insulin-dependent diabetes mellitus in families: islet cell antibodies and HLA DQ heterodimers. , 1992, American journal of epidemiology.

[2]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[3]  D. Rao,et al.  Phenotypic effects of apolipoprotein structural variation on lipid profiles: II. Apolipoprotein A‐IV and quantitative lipid measures in the healthy women study , 1989, Genetic epidemiology.

[4]  A. Brøgger,et al.  Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. , 1994, Cancer research.

[5]  B. Conrad,et al.  Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. , 1994, Diabetes/metabolism reviews.

[6]  E. Meilahn,et al.  Phenotypic effects of apolipoprotein structural variation on lipid profiles. III. Contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the healthy women study. , 1990, Arteriosclerosis.

[7]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. , 1995, American journal of obstetrics and gynecology.

[8]  K. Nakachi,et al.  Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. , 1993, Cancer research.

[9]  C. Sing,et al.  Effects of polymorphisms in apolipoproteins E, A-IV, and H on quantitative traits related to risk for cardiovascular disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[10]  L. Kuller,et al.  Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. , 1993, The American journal of cardiology.

[11]  C. Amos,et al.  Host factors in lung cancer risk: a review of interdisciplinary studies. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  M. Khoury,et al.  Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. , 1995, American journal of human genetics.

[13]  Paul A. Schulte,et al.  Molecular epidemiology : principles and practices , 1993 .

[14]  M. Trucco,et al.  The genes influencing the susceptibility to IDDM in humans , 1994, Journal of endocrinological investigation.

[15]  E. Mark,et al.  Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. , 1995, Cancer research.

[16]  B. Dahlbäck Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. , 1995, Blood.

[17]  C. Sing,et al.  Genetic architecture of common multifactorial diseases. , 1996, Ciba Foundation symposium.

[18]  J. Dorman Molecular Epidemiology and DNA Technology Transfer: A Program for Developing Countries , 1994 .

[19]  R E LaPorte,et al.  Worldwide differences in the incidence of type I diabetes are associated with amino acid variation at position 57 of the HLA-DQ beta chain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Beaty,et al.  Fundamentals of Genetic Epidemiology , 1993 .

[21]  H. Schut,et al.  DNA adducts in humans as dosimeters of exposure to environmental, occupational, or dietary genotoxins 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[23]  J. Todd,et al.  Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Ottman Gene-environment interaction and public health. , 1995, American journal of human genetics.

[25]  F R Rosendaal,et al.  Factor V Leiden: should we screen oral contraceptive users and pregnant women? , 1996, BMJ.

[26]  B. Conrad,et al.  Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology , 1994, Nature.

[27]  M. Trucco,et al.  To Be Or Net To Be ASP 57, That Is The Question , 1992, Diabetes Care.

[28]  C. Sing,et al.  Influences of common variants of apolipoprotein E on measures of lipid metabolism in a sample selected for health. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[29]  J. Hixson Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  J. Dorman Standardization of Epidemiologic Studies of Host Susceptibility , 1994, NATO ASI Series.

[31]  D. Rao,et al.  Phenotypic effects of apolipoprotein structural variation on lipid profiles. IV. Apolipoprotein polymorphisms in a small group of black women from the Healthy Women Study , 1989, Genetic epidemiology.

[32]  S. Mann,et al.  Ciba Foundation Symposium , 1997 .

[33]  N. Relkin,et al.  Apolipoprotein E genotyping in Alzheimer's disease , 1996, The Lancet.